Literature DB >> 28690977

Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis.

Michael I Carr1, Stephen N Jones1.   

Abstract

The p53 tumor suppressor acts as a guardian of the genome in mammalian cells undergoing DNA double strand breaks induced by a various forms of cell stress, including inappropriate growth signals or ionizing radiation. Following damage, p53 protein levels become greatly elevated in cells and p53 functions primarily as a transcription factor to regulate the expression a wide variety of genes that coordinate this DNA damage response. In cells undergoing high amounts of DNA damage, p53 can promote apoptosis, whereas in cells undergoing less damage, p53 promotes senescence or transient cell growth arrest and the expression of genes involved in DNA repair, depending upon the cell type and level of damage. Failure of the damaged cell to undergo growth arrest or apoptosis, or to respond to the DNA damage by other p53-coordinated mechanisms, can lead to inappropriate cell growth and tumorigenesis. In cells that have successfully responded to genetic damage, the amount of p53 present in the cell must return to basal levels in order for the cell to resume normal growth and function. Although regulation of p53 levels and function is coordinated by many proteins, it is now widely accepted that the master regulator of p53 is Mdm2. In this review, we discuss the role(s) of p53 in the DNA damage response and in tumor suppression, and how post-translational modification of Mdm2 regulates the Mdm2-p53 signaling axis to govern p53 activities in the cell.

Entities:  

Keywords:  DNA damage; Tumor suppressor p53; carcinogenesis; oncoprotein Mdm2; protein stability

Year:  2016        PMID: 28690977      PMCID: PMC5501481          DOI: 10.21037/tcr.2016.11.75

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN: 2218-676X            Impact factor:   1.241


  259 in total

1.  c-Abl neutralizes the inhibitory effect of Mdm2 on p53.

Authors:  R V Sionov; E Moallem; M Berger; A Kazaz; O Gerlitz; Y Ben-Neriah; M Oren; Y Haupt
Journal:  J Biol Chem       Date:  1999-03-26       Impact factor: 5.157

2.  Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination.

Authors:  S Nakamura; J A Roth; T Mukhopadhyay
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  Downregulation of MDM2 expression by RNAi inhibits LoVo human colorectal adenocarcinoma cells growth and the treatment of LoVo cells with mdm2siRNA3 enhances the sensitivity to cisplatin.

Authors:  Yan Yu; Ping Sun; Li-chun Sun; Guo-yi Liu; Guo-hua Chen; Li-hua Shang; Hong-bo Wu; Jing Hu; Yue Li; Yin-ling Mao; Guang-jie Sui; Xi-wen Sun
Journal:  Biochem Biophys Res Commun       Date:  2005-11-08       Impact factor: 3.575

4.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

5.  Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation.

Authors:  A Damalas; S Kahan; M Shtutman; A Ben-Ze'ev; M Oren
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

6.  DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells.

Authors:  W Nieves-Neira; M I Rivera; G Kohlhagen; M L Hursey; P Pourquier; E A Sausville; Y Pommier
Journal:  Mol Pharmacol       Date:  1999-09       Impact factor: 4.436

7.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

8.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

9.  Absence of p21 partially rescues Mdm4 loss and uncovers an antiproliferative effect of Mdm4 on cell growth.

Authors:  Heather A Steinman; Hayla K Sluss; Arthur T Sands; German Pihan; Stephen N Jones
Journal:  Oncogene       Date:  2004-01-08       Impact factor: 9.867

10.  Phosphorylation of Daxx by ATM contributes to DNA damage-induced p53 activation.

Authors:  Jun Tang; Trisha Agrawal; Qian Cheng; Like Qu; Michael D Brewer; Jiandong Chen; Xiaolu Yang
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

View more
  15 in total

1.  Synthesis and Characterization of Plumbagin S-Allyl Cysteine Ester: Determination of Anticancer Activity In Silico and In Vitro.

Authors:  Sudha Vijayan; Chitra Loganathan; Penislusshiyan Sakayanathan; Palvannan Thayumanavan
Journal:  Appl Biochem Biotechnol       Date:  2022-07-12       Impact factor: 3.094

2.  Loss of Both USP10 and p14ARF Protein Expression Is an Independent Prognostic Biomarker for Poor Prognosis in Patients With Epithelial Ovarian Cancer.

Authors:  Gwan Hee Han; Doo Byung Chay; Joo Mi Yi; Hanbyoul Cho; Joon-Yong Chung; Jae-Hoon Kim
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

Review 3.  The Regulation of JNK Signaling Pathways in Cell Death through the Interplay with Mitochondrial SAB and Upstream Post-Translational Effects.

Authors:  Sanda Win; Tin Aung Than; Neil Kaplowitz
Journal:  Int J Mol Sci       Date:  2018-11-20       Impact factor: 5.923

4.  Deciphering the Mammary Stem Cell Niche: A Role for Laminin-Binding Integrins.

Authors:  Mathilde Romagnoli; Stéphanie Cagnet; Aurélie Chiche; Laura Bresson; Sylvain Baulande; Pierre de la Grange; Adèle De Arcangelis; Maaike Kreft; Elisabeth Georges-Labouesse; Arnoud Sonnenberg; Marie-Ange Deugnier; Karine Raymond; Marina A Glukhova; Marisa M Faraldo
Journal:  Stem Cell Reports       Date:  2019-03-21       Impact factor: 7.765

5.  Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies.

Authors:  Pierre Gâtel; Frédérique Brockly; Christelle Reynes; Manuela Pastore; Yosr Hicheri; Guillaume Cartron; Marc Piechaczyk; Guillaume Bossis
Journal:  Life Sci Alliance       Date:  2020-04-17

Review 6.  Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration.

Authors:  Tzu-Hua Chen-Liang
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

7.  A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein.

Authors:  Georgios Valianatos; Barbora Valcikova; Katerina Growkova; Amandine Verlande; Jitka Mlcochova; Lenka Radova; Monika Stetkova; Michaela Vyhnakova; Ondrej Slaby; Stjepan Uldrijan
Journal:  PLoS One       Date:  2017-10-03       Impact factor: 3.240

Review 8.  The Role of MDM2 in Promoting Genome Stability versus Instability.

Authors:  M Reza Saadatzadeh; Adily N Elmi; Pankita H Pandya; Khadijeh Bijangi-Vishehsaraei; Jixin Ding; Christopher W Stamatkin; Aaron A Cohen-Gadol; Karen E Pollok
Journal:  Int J Mol Sci       Date:  2017-10-23       Impact factor: 5.923

9.  USP7-Dependent Regulation of TRAF Activation and Signaling by a Viral Interferon Regulatory Factor Homologue.

Authors:  Qiwang Xiang; Hyunwoo Ju; John Nicholas
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

10.  Cross-talk between Myc and p53 in B-cell lymphomas.

Authors:  Li Yu; Tian-Tian Yu; Ken H Young
Journal:  Chronic Dis Transl Med       Date:  2019-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.